On day 2 of the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, we spoke with Ali McBride, PharmD, MS, BCPS, BCOP, clinical coordinator of hematology/oncology in the Department of Pharmacy at The University of Arizona Cancer Center, and James Hamrick, MD, senior medical director at Flatiron Health.
Today-
We are on site in Washington, DC, for day 2 of the Association of Community Cancer Centers’ Annual Meeting and Cancer Center Business Summit!
We will be recapping some of the top news presented each day during the meeting—and soon we’ll speak with James Hamrick, MD, senior medical director of Flatiron Health, and Ali McBride, PharmD, MS, BCPS, BCOP, incoming president of ACCC.
Welcome to AJMC® On Location! I’m Jaime Rosenberg.
The second day of the meeting focused on technology in healthcare and the digital health revolution. There was a session on likely innovations in health IT over the next 18 years based on insights from leaders in government, academia, and industry. In addition, there was a panel discussion on how wearables are generating patient-reported outcomes and empowering providers to be able to better manage symptoms and improve resource utilization.
Read about these stories and watch additional interviews from the meeting at AJMC.com.
That’s all from the ACCC Annual Meeting and Cancer Center Business Summit. Join us again April 4-5, when we will be reporting on site at the Community Oncology Alliance’s Community Oncology Conference being held in Orlando, Florida.
Thank you for watching AJMC® News Network! I’m Jaime Rosenberg.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More